Business
Tesco not ‘losing grip’ on UK grocery market despite persistent price war
Tesco is showing no signs of “losing its grip” as the UK’s biggest supermarket – despite battling an persistent price war and a plethora of higher business costs, experts say.
Investors will be hoping the grocery giant is maintaining sales growth when it publishes its half-year financial results on Thursday.
Tesco revealed its group sales rose by 4.6% in its first quarter, compared with the prior year, having been boosted by growing demand for own-brand and premium products.
It has been steadily growing its share of the UK grocery market – picking up 0.8 percentage points over the past year to 28.4%, according to the latest analysis by Worldpanel by Numerator.
Meanwhile, its biggest rivals Sainsbury’s and Asda have seen their share of the market edge lower, while German discounters Aldi and Lidl continue to gain customers.
Tesco’s shares have soared to their highest price in more than a decade amid the strengthening performance.
Richard Hunter, head of markets for Interactive Investor, said: “Expectations will be high as ever for the supermarket, although at the first quarter numbers in June there were no signs that the company was losing its grip on dominating the British aisles.
“Indeed, the juggernaut powered on, maintaining the light between the group and its nearest rivals.”
However, Tesco’s boss Ken Murphy acknowledged at the company’s most recent trading update that the grocery market was “intensely competitive”.
It comes amid continued pressure on pricing from rival supermarkets, with Asda slashing prices this year in a bid to help turn around its fortunes.
In April, Tesco said it expects to make as much as £400 million less in profit this financial year due to heightened competition.
Mr Hunter said the prospect of a grocery price war was “not one which Tesco is taking lightly, and is mindful of a renewed attack from Asda”.
He added that any updates to its annual profit forecast on Thursday would be “warmly received” by shareholders.
A group of analysts for AJ Bell said the grocery price war is expected to impact profits, but that Tesco was also experiencing “input cost pressure, notably wages, national insurance contributions and food prices”.
It is among major retailers to back calls to the Government to limit further tax rises on the industry, as they warn it is becoming increasingly difficult to “absorb” higher costs.
It comes amid concerns about food inflation, which has been accelerating for five months in a row.
Business
Anthropic officially designated a supply chain risk by Pentagon
The supply chain risk designation of the artificial intelligence firm is a first for a US company.
Source link
Business
FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease
Thomas Fuller | SOPA Images | Lightrocket | Getty Images
UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday.
The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn’t ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed.
“So what is really going on? UniQure is the latest company to make a failed therapy for Huntington’s patients,” the official said. “They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA.”
The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Quick last week seemingly criticized UniQure’s gene therapy for Huntington’s disease. Makary didn’t name UniQure but described its treatment.
UniQure then accused the FDA of reversing its stance that the company’s clinical trial data would be sufficient to seek approval. UniQure’s study used an outside database to measure how patients with Huntington’s disease might decline without treatment, known as an external control. UniQure has said it wouldn’t be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn’t be ethical to make people undergo a sham hours-long brain surgery.
The FDA official said the agency “never agreed to accept this distorted comparison” and the FDA “never makes such assurances.” Instead, the “FDA will always say, ‘Well, we have to see the data when we get it.'”
UniQure didn’t immediately comment.
The company’s stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.
Business
US mortgage rates rise to 6% after three-week slide as oil-driven bond yields climb – The Times of India
The average long-term US mortgage rate edged higher this week, ending a three-week decline as bond yields rose amid oil-price pressures linked to the war with Iran.The benchmark 30-year fixed mortgage rate increased to 6% from 5.98% last week, mortgage buyer Freddie Mac said on Thursday. A year ago, the average rate stood at 6.63%, AP reported.The modest uptick breaks a three-week slide in borrowing costs, with mortgage rates having hovered close to the 6% mark for most of this year. Last week’s average had marked the first time the rate dipped below 6% since September 2022, reaching its lowest level in nearly three and a half years.Mortgage rates are influenced by several factors, including the Federal Reserve’s interest-rate policy, investor expectations about inflation and economic growth, and movements in the bond market.They typically track the direction of the 10-year US Treasury yield, which lenders use as a benchmark for pricing home loans.The 10-year Treasury yield rose to 4.14% at midday Thursday, up from around 4% a week earlier.Treasury yields have moved higher in recent days as rising oil prices added fresh inflation concerns, potentially complicating the Federal Reserve’s plans to cut interest rates.
-
Politics1 week agoWhat are Iran’s ballistic missile capabilities?
-
Business7 days agoIndia Us Trade Deal: Fresh look at India-US trade deal? May be ‘rebalanced’ if circumstances change, says Piyush Goyal – The Times of India
-
Business1 week agoAttock Cement’s acquisition approved | The Express Tribune
-
Politics1 week agoUS arrests ex-Air Force pilot for ‘training’ Chinese military
-
Fashion1 week agoPolicy easing drives Argentina’s garment import surge in 2025
-
Business6 days agoGreggs to reveal trading amid pressure from cost of living and weight loss drugs
-
Sports6 days agoLPGA legend shares her feelings about US women’s Olympic wins: ‘Gets me really emotional’
-
Fashion7 days agoTexwin Spinning showcasing premium cotton yarn range at VIATT 2026
